Results 131 to 140 of about 3,864 (165)

Body mass index and nutritional intake following Elexacaftor/Tezacaftor/Ivacaftor modulator therapy in adults with cystic fibrosis [PDF]

, 2023
L.R. Caley, Heledd Jarosz-Griffiths, Lesley Smith, L. Gale, Joanne Barrett, L. Kinsey, Valerie A. Davey, M. Nash, Andrew Jones, J.L. Whitehouse, D. Shimmin, R. Andres Floto, H. White, D. Peckham   +13 more
openalex   +1 more source

Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment [PDF]

Sarah J. Morgan, Ellis Coulter, Hannah L Betts, George M. Solomon, John Clancy, Steven M. Rowe, David P. Nichols, Pradeep K. Singh   +7 more
openalex   +1 more source

Design and synthesis of photoaffinity labeling probes based on clinically approved CFTR modulators [PDF]

, 2022
Hamilton, Christopher Michael, Hamilton, Christopher Michael   +1 more
core  

172 Treatment changes and outcomes in adults taking elexacaftor/tezacaftor/ivacaftor at two years: A single-center experience

, 2022
Q. Azeem, J. Yeley, H. Vogt, C. Powers, C. Brown   +4 more
openalex   +1 more source

Corrigendum: Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats [PDF]

Nicole Reyne, Patricia Cmielewski, Alexandra McCarron, Ronan Smith, Elena K. Schneider‐Futschik, Nina Eikelis, Piraveen Pirakalathanan, David Parsons, Martin Donnelley   +8 more
openalex   +1 more source

P216 The impact of the COVID-19 pandemic and elexacaftor/tezacaftor/ivacaftor initiation on high-cost medication utilisation in adults living with cystic fibrosis [PDF]

, 2023
M.S. Suhel, Amy Hai Yan Chan, D. Nazareth, D Wat, Martin Walshaw, D. Green, Freddy Frost   +6 more
openalex   +1 more source

484 Change in pulmonary infections 12 months after elexacaftor/tezacaftor/ivacaftor introduction: Results from the Danish National Cystic Fibrosis Cohort

, 2022
M. Jeppesen, S. Jensen-Fangel, C. Leo-Hansen, C. Højte, M. Olsen, M. Wang, M.P. Bendixen, H. Johansen, Camilla Bjørn Jensen, T. Pressler, M. Skov, H. Olesen, D. Faurholt-Jepsen, T. Lea Katzenstein, T. Qvist   +14 more
openalex   +1 more source

724 Efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in a cohort of older people with cystic fibrosis

, 2023
Bryan Garcia, G. Caleb, Julianna Bailey, Stefanie Krick   +3 more
openalex   +1 more source

Equity in Cystic Fibrosis Care: Addressing Racial Disparities in Cystic Fibrosis Treatment [PDF]

Introduction: Cystic fibrosis (CF) is historically underdiagnosed in Black populations, in part due to symptom misattribution and diagnostic frameworks centered around White patient presentations.
Khan, Manahil
core  

Real‐World Improvements of Lung Clearance Index and Ventilation Distribution Efficiency in Children With Cystic Fibrosis After Elexacaftor/Tezacaftor/Ivacaftor Initiation [PDF]

Esben Herborg Henriksen, Rikke Mulvad Sandvik, Mette Frahm Olsen, Tacjana Pressler, Thomas Bryrup, Christian Leo‐Hansen, Bibi Uhre Nielsen, Christine Højte, Marianne Skov, Frederik Buchvald, Inger Hee Mabuza Mathiesen, Tavs Qvist, Hanne Vebert Olesen, Sune Rubak, Camilla Bjørn Jensen, Daniel Faurholt‐Jepsen, Kim G. Nielsen, TransformCF Study Group   +17 more
openalex   +1 more source